Sector News

Novartis plots 400 job cuts in India after striking sales pact with Dr. Reddy’s

February 20, 2022
Life sciences

A bid to boost access to Novartis’ drugs in India is putting hundreds of jobs on the chopping block.

Novartis India has forged an exclusive sales and distribution pact with Dr. Reddy’s Laboratories centered on certain established meds, including the pain-relief drug Voveran and Methergine, which is used to treat severe bleeding from the uterus after childbirth.

The pact is meant to broaden access to the meds beyond their current geographies, which Novartis and Dr. Reddy’s will accomplish “by significantly extending the reach of healthcare professionals through an expanded field force,” Novartis said. The deal will fuse Novartis India’s manufacturing and development know-how with Dr. Reddy’s sales and distribution muscle, the company said.

Novartis India plans to cut 400 jobs with the move. The company says it understands “the implications of this difficult decision,” so it’s offering employees a severance package and outplacement services.

Novartis employs more than 10,000 full-time staffers in India, the company said. Since January 2020, the company has hired more than 1,600 employees worldwide. Novartis’ Indian outfits plan to continue this hiring push in 2022, the company noted.

Meanwhile, Novartis is investing to upgrade its R&D and manufacturing footprint in the country. Over the past five years, it has spent more than $300 million on an Indian R&D support center, for instance.

Elsewhere in the country, the company is building out a $49 million manufacturing plant at Kalwe, which will manufacture oral cancer meds for the global market.

The Dr. Reddy’s news comes as Novartis conducts a strategic review of its generic unit, Sandoz. Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Sandoz, Bloomberg has said, citing people close to the matter. Novartis says it will provide an update on its plan for the generics outfit by the end of the year.

by Fraiser Kansteiner

Source: fiercepharma.com

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).